<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lisinopril reduces mortality in patients with diabetes after acute MI</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lisinopril reduces mortality in patients with diabetes after acute MI</h1>
<div class="graphic"><div class="figure"><div class="ttl">Lisinopril reduces mortality in patients with diabetes after acute MI</div><div class="cntnt"><img src="data:png;base64,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"/></div><div class="graphic_lgnd">The GISSI-3 trial enrolled 18,131 patients of whom 2790 were diabetics. Treatment with lisinopril was associated with a significant 29.8 percent reduction in the six-week mortality among diabetics after myocardial infarction (MI), translating into 37 lives saved per 1000 patients. Lisinopril was less effective in nondiabetics; there was only a 5 percent reduction in mortality or three lives saved per 1000 patients.</div><div class="graphic_reference">Data from Zuanetti G, Latini R, Maggioni AP, et al, for the GISSI-3 Investigators. Circulation 1997; 96:4239.</div><div id="graphicVersion">Graphic 63118 Version 3.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
